DNA repair mechanisms and their clinical impact in glioblastoma (Q26740256)

title

DNA repair mechanisms and their clinical impact in glioblastoma (English)

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Hélène Erasimus

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Matthieu Gobin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Eric Van Dyck

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

2016

1 reference

Mutation Research - Reviews

PubMed

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

19-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

KUB3 amplification and overexpression in human gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Oxidative stress and apoptosis: impact on cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Alternative lengthening of telomeres in human glioma stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA methyltransferases, DNA damage repair, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA glycosylases: in DNA repair and beyond

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A survey of glioblastoma genomic amplifications and deletions

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Driver mutations of cancer epigenomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

HDAC inhibitors: roles of DNA damage and repair

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA ligase IV as a new molecular target for temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Genetic Classification of Gliomas: Refining Histopathology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Histone H3.3 mutations: a variant path to cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Principles of cancer therapy: oncogene and non-oncogene addiction

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The somatic genomic landscape of glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Mouse models of DNA double-strand break repair and neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Validation of an imageable surgical resection animal model of Glioblastoma (GBM).

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The DNA Damage Response: Making It Safe to Play with Knives

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ATM and ATR as therapeutic targets in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso)pyrimidine derivatives and analogues

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A restricted cell population propagates glioblastoma growth after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Strategies to improve radiotherapy with targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA interstrand crosslink repair and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Balancing repair and tolerance of DNA damage caused by alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Unravelling mechanisms of p53-mediated tumour suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Understanding nucleotide excision repair and its roles in cancer and ageing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

MGMT testing--the challenges for biomarker-based glioma treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA binding and nucleotide flipping by the human DNA repair protein AGT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Predictive biomarkers for cancer therapy with PARP inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The evidence of glioblastoma heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Reversal of DNA alkylation damage by two human dioxygenases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

In vivo models of primary brain tumors: pitfalls and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The role of double-strand break repair pathways at functional and dysfunctional telomeres

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNA repair and cancer: lessons from mutant mouse models

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Genetically engineered mouse models of brain cancer and the promise of preclinical testing

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Extended survival of glioblastoma patients after chemoprotective HSC gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Replication past O(6)-methylguanine by yeast and human DNA polymerase eta.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Key concepts in glioblastoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Alkylation sensitivity screens reveal a conserved cross-species functionome

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Base excision repair defects invoke hypersensitivity to PARP inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Mechanisms of resistance to PARP inhibitors--three and counting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Chemoresistance of glioblastoma cancer stem cells--much more complex than expected

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Clinical significance of Polycomb gene expression in brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Experience with irinotecan for the treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

MiR-221/222 target the DNA methyltransferase MGMT in glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Roles of Long Non-Coding RNAs on Tumorigenesis and Glioma Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Targeting the microRNA-regulating DNA damage/repair pathways in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

New strategies to deliver anticancer drugs to brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Reactive oxygen species in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

The strategy for enhancing temozolomide against malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Ionizing radiation in glioblastoma initiating cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Is glioblastoma an epigenetic malignancy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Gliadel wafers in the treatment of malignant glioma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Effect of IFN-beta on human glioma cell lines with temozolomide resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

ID1 regulates U87 human cell proliferation and invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

Exploiting synthetic lethal interactions for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MRREV.2016.05.005

7 January 2021

10.1016/J.MRREV.2016.05.005

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27543314%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference